MS & Immune Disorders

Filter Your Results

 

News

 

New Data Available on Risk of Relapse During Pregnancy for Women With Multiple Sclerosis

Tuesday, October 23, 2018—Multiple sclerosis (MS) most often affects women of childbearing age, making family planning and management of the disease before, during, and after pregnancy a primary concer…

Evobrutinib—A First-in-Class Drug—Shows Efficacy in Phase 2 Clinical Trials

Friday, October 12, 2018—October 12, 2018 -- At the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, German October 10-12, results from a double-blind pl…

Dimethyl Fumarate Has Low Risk of Progressive Multifocal Leukoencephalopathy, Short Duration of Lymphopenia, and Long-Term Efficacy for Relapsing Multiple Sclerosis

Friday, October 12, 2018—At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany October 10-12, results were reported from an integrated analysi…

Cladribine Extension Trial and Post Hoc Analysis Shows 10-Year Safety and Efficacy

Friday, October 12, 2018—In data presented at the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany Oct. 10-12, real-world follow up and post-hoc …

Ocrelizumab Reduces Upper Limb Disability for Patients With Progressive Multiple Sclerosis

Thursday, October 11, 2018—October 11, 2018 -- Results from new analysis of the phase 3 ORATORIO study (NCT01194570) were presented at the European Committee for Treatment and Research in Multiple Scler…

Natalizumab Has Long Term Efficacy and Safety That is Well Controlled With Use of the JCV Index

Thursday, October 11, 2018—In results presented at the European Committee on Treatment and Research for Multiple Sclerosis (ECTRIMS) conference in Berlin, Germany, data on the use of natalizumab (NTZ) (…

Alemtuzumab Has Continued Efficacy for Patients With Multiple Sclerosis After 8 years of Follow-Up

Thursday, October 11, 2018—Phase 3 extension studies for alemtuzumab (Lemtrada; Sanofi-Genzyme, Cambridge, MA) has continued efficacy after 8 years of treatment according to results presented at the Eur…

Long-Term Efficacy of Ocrelizumab Treatment for People with Relapsing Multiple Sclerosis

Wednesday, October 10, 2018—Multiple results regarding use of ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for treatment of patients with multiple sclerosis (MS) were presented today at the …

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC